Lansforsakringar Fondforvaltning AB publ Acquires 17,438 Shares of Thermo Fisher Scientific Inc. $TMO

30 Jun 2026, 09:33 by Michael Walen · The Markets Daily

Lansforsakringar Fondforvaltning AB publ grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 14.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 138,295 shares of the medical research company’s stock after buying an additional 17,438 shares during the quarter. Lansforsakringar Fondforvaltning AB publ’s holdings in Thermo Fisher Scientific were worth $67,976,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in shares of Thermo Fisher Scientific by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company’s stock worth $19,778,774,000 after purchasing an additional 288,296 shares during the last quarter. J. Stern & Co. LLP grew its holdings in Thermo Fisher Scientific by 58,006.4% during the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock worth $18,258,082,000 after buying an additional 31,455,105 shares in the last quarter. State Street Corp raised its position in Thermo Fisher Scientific by 1.4% in the 4th quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock valued at $9,633,991,000 after buying an additional 229,630 shares during the last quarter. Capital World Investors boosted its holdings in Thermo Fisher Scientific by 7.0% during the 4th quarter. Capital World Investors now owns 11,003,814 shares of the medical research company’s stock worth $6,376,229,000 after acquiring an additional 718,669 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Thermo Fisher Scientific by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company’s stock valued at $4,728,129,000 after purchasing an additional 26,425 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity

In related news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares in the company, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on TMO. Robert W. Baird cut their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Piper Sandler started coverage on Thermo Fisher Scientific in a research note on Thursday, June 11th. They issued a “neutral” rating and a $510.00 target price on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Barclays dropped their price target on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a report on Tuesday, April 14th. Finally, Wall Street Zen downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $605.09.

Check Out Our Latest Report on Thermo Fisher Scientific

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $505.09 on Tuesday. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. The stock has a fifty day simple moving average of $473.86 and a two-hundred day simple moving average of $519.44. Thermo Fisher Scientific Inc. has a 1-year low of $401.45 and a 1-year high of $643.99. The firm has a market cap of $187.70 billion, a price-to-earnings ratio of 27.77, a price-to-earnings-growth ratio of 2.27 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last issued its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. During the same period in the previous year, the company posted $5.15 earnings per share. The business’s revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Analysts anticipate that Thermo Fisher Scientific Inc. will post 24.85 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be given a $0.47 dividend. The ex-dividend date is Monday, June 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific’s payout ratio is 10.34%.

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.